Daré Bioscience announces the return of all rights to Ovaprene® from Bayer HealthCare LLC.
The Phase 3 program for Ovaprene is ongoing with non-dilutive grant support.
Positive interim data from July 2025 reinforces the asset's potential.
Consolidation of commercialization rights strengthens Daré's strategic position.
Ovaprene has the potential to be the first FDA-approved hormone-free intravaginal contraceptive.
Strategic Prioritization by Bayer
Bayer HealthCare LLC terminates license agreement, returning rights to Daré by February 2026.
Positive Interim Data
July 2025 interim results show consistent safety, tolerability, and favorable pregnancy rates in study.
Increased Optionality for Daré
Consolidated global commercialization rights open doors for strategic partnerships and value maximization.
Clear Path Forward
Phase 3 study enrollment completion by 2026 with premarket approval strategy with the FDA.
Innovative Contraceptive Technology
Ovaprene combines physical and chemical mechanisms, offering a hormone-free, self-administered monthly contraceptive option.
- The return of rights to Ovaprene provides Daré with full control of a late-stage asset in a significant market segment.
- Consolidation of commercialization rights enhances Daré's strategic flexibility and potential for value creation.
- Positive interim results from the Phase 3 trial support Ovaprene's clinical and commercial promise.
- Expanded optionality allows Daré to explore diverse partnership structures and maximize the asset's market value.
Daré Bioscience's regained control of Ovaprene marks a strategic milestone towards FDA approval and commercial success. The positive interim data reinforces the potential of this innovative contraceptive. With a clear path forward and increased strategic optionality, Daré is well-positioned to shape the future of women's health solutions.